Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC boosted its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 34.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 23,550 shares of the biotechnology company’s stock after buying an additional 6,000 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Iovance Biotherapeutics were worth $174,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in IOVA. EverSource Wealth Advisors LLC purchased a new stake in Iovance Biotherapeutics in the second quarter valued at $58,000. ORG Wealth Partners LLC purchased a new stake in shares of Iovance Biotherapeutics in the third quarter worth about $89,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Iovance Biotherapeutics by 31.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,978 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 2,624 shares during the period. B. Riley Wealth Advisors Inc. purchased a new position in Iovance Biotherapeutics during the second quarter valued at approximately $107,000. Finally, Assetmark Inc. lifted its holdings in Iovance Biotherapeutics by 48.0% in the third quarter. Assetmark Inc. now owns 12,853 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 4,167 shares during the period. 77.03% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Iovance Biotherapeutics

In other news, Director Ryan D. Maynard sold 50,000 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total transaction of $503,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $75,450. This represents a 86.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on IOVA shares. UBS Group assumed coverage on shares of Iovance Biotherapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Iovance Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $23.00.

Iovance Biotherapeutics Stock Up 1.9 %

Shares of NASDAQ IOVA opened at $5.99 on Thursday. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -4.02 and a beta of 0.57. The company’s 50-day simple moving average is $7.71 and its 200-day simple moving average is $9.11. Iovance Biotherapeutics, Inc. has a 52-week low of $5.57 and a 52-week high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.03. The company had revenue of $58.56 million during the quarter, compared to analyst estimates of $53.54 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. During the same period in the previous year, the business earned ($0.46) EPS. Equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.